Afreen Shariff, Associate Director of the Cancer Therapy Toxicity Program at the Center for Cancer Immunotherapy, Duke Cancer InstituteCenter, shared a post on LinkedIn:
“T minus 2 days to the 2nd ASPIRE and 3rd NICT conference.
Looking forward to a rich discussion with representatives regionally, nationally and internationally to discuss the vision for the future, right at the intersection of patient advocacy, irAE management, clinical trials, novel drug development and interventional trials.
Thank you to all our sponsors, speakers and supporters.”
More posts featuring Afreen Shariff.